YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Kazia Therapeutics Limited (NASDAQ:KZIA) has materially strengthened its financing position, but the clinical case for expanding paxalisib into HR-positive, HER2-negative metastatic breast cancer remains at the preclinical stage. Paxalisib…
DelveInsight Business Research LLP The glioma market is expected to witness steady growth over the coming years, driven by the rising incidence of primary brain tumors, increasing awareness, and advances in diagnostic technologies. The mar…
SYDNEY, July 28, 2026 (GLOBE NEWSWIRE) -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistanc…
We just covered 15 Under-the-Radar Picks from David Einhorn That Are Quietly Dominating 2026 and Roivant Sciences Ltd. (NASDAQ:ROIV) ranks 7th on this list. Roivant Sciences Ltd. (NASDAQ:ROIV) has been a consistent feature in the 13F portf…
Kazia Therapeutics Ltd (NASDAQ:KZIA) is among the best Australian stocks to buy in 2026. Kazia Therapeutics Ltd (NASDAQ:KZIA) recently strengthened its team and expanded its platform as it works to address unmet needs in the cancer treatme…
Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA), a clinical-stage…
(RTTNews) - A quiet news day didn't stop several high-volatility healthcare and cannabis stocks from posting sharp after-hours gains on Friday, with traders leaning into recent catalysts and technical momentum. Tilray Brands, Inc. (TLRY):…
DENVER, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Investors are digesting major developments across the energy, tech, oncology, and entertainment sectors. Nuclear Power Roars Back: DOE Backs Constellation’s Crane Clean Energy Center Constellation…
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT YYGH [https://www.chartmill.com/stock/quo…
Kazia Therapeutics (NASDAQ:KZIA) on Wednesday reported preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab), and standard chemo…
SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and st…
If you’ve read all the warnings and still want to jump into some of the top penny stocks to buy, focus on the key fundamentals. That includes its earnings numbers, business models, product pipelines and what market they’re part of. You’ll…
In this piece, we will take a look at the 11 best ASX stocks to buy now. If you want to skip our introduction to the Australian stock market, then you can take a look at the 5 Best ASX Stocks To Buy Now. With a market capitalization of $1.…
SYDNEY, July 6, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that its lead program, paxalisib, has been awarded Fast Track Designation (FTD)…
Quite a few insiders have dramatically grown their holdings in Kazia Therapeutics Limited (ASX:KZA) over the past 12 months. An insider's optimism about the company's prospects is a positive sign. While insider transactions are not the mos…
SYDNEY, June 8, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it is supporting the University of Sydney on a molecularly-guided phase II…
Brain Cancers Forum on Glioblastoma & Diffuse Intrinsic Pontine Glioma Forum SYDNEY, May 25, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, has been invited to the Wh…
SYDNEY, April 14, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to have received notification from the Listing Qualifications Staff (the "Staff") of the N…
SYDNEY, April 4, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data for both of its pipeline molecules, paxalisib and…
Two of the three most widely followed indexes ended the week in the red. The Dow Jones Industrial Average and the S&P 500 declined 0.1% and 0.3%, respectively, while the Nasdaq Composite advanced 0.6%. A slew of economic data released thro…
A downtrend has been apparent in Novogen Limited (KZIA) lately. While the stock has lost 5.4% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the…
Those following along with Kazia Therapeutics Limited (ASX:KZA) will no doubt be intrigued by the recent purchase of shares by insider Stephen Abolakian, who spent a stonking AU$1m on stock at an average price of AU$0.12. That purchase boo…
Melbourne, Victoria --News Direct-- Kazia Therapeutics Ltd Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) CEO Dr James Garner speaks with Proactive after confirming a two-tranche capital raising initiative to raise A$4.5 million through pla…
SYDNEY, Jan. 16, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce a placement of KZA shares, to institutional and sophisticated investors…
LONDON, UK / ACCESSWRE / December 19, 2022 / Kazia Therapeutics has announced a research collaboration with QIMR Berghofer Medical Research Institute (an Australia-based cancer research center) to investigate the utility of its lead asset,…
SYDNEY, Dec. 15, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce a collaboration with QIMR Berghofer Medical Research Institute, one of Australi…
SYDNEY, Dec. 12, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) received a deficiency notification from the Listing Qualifications Staff of the Nasdaq Stock Market LLC, dated December 9, 2022, notifying the compan…
SYDNEY, Dec. 1, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication of positive preclinical data for EVT801, a clinical-stage drug c…
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Kazia Therapeutics Limited's (ASX:KZA) case, it's fantastic news for shareholders. While insider transactions are n…
SYDNEY, Nov. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed g…
LONDON, UK / ACCESSWIRE / November 2, 2022 / Kazia Therapeutics' Q123 cash flow report provided an update on the company's financial position and business progress. While the quarter was dominated by lead asset paxalisib hitting a roadbloc…
Kazia Therapeutics Limited (NASDAQ: KZIA) announced new data from an ongoing research collaboration with the Huntsman Cancer Institute at the University of Utah. A poster presentation showed that paxalisib is active in vitro and in vivo ag…
SYDNEY, Oct. 27, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data from an ongoing research collaboration with the Hu…
SYDNEY, Oct. 6, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that an ongoing phase II study of paxalisib, an investigational drug for the treatment…
A downtrend has been apparent in Novogen Limited (KZIA) lately. While the stock has lost 21% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the b…
SYDNEY, Sept. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the upcoming 24th Annual Globa…